Shots:
- Approval of Optune Lua for adults with unresectable advanced/recurrent NSCLC who progressed on Pt-based regimen, was based on P-III (LUNAR) trial assessing it with PD-1/PD-L1 inhibitors or docetaxel (n=145) vs PD-1/PD-L1 inhibitors or docetaxel alone (n=146)
- Trial showed an mOS (1EP) of 13.2 vs 9.9mos. in the overall population, 19 vs 10.8mos. with Optune Lua + PD-1/PD-L1 inhibitor (n=70) vs PD-1/PD-L1 inhibitor (n=71) & 11.1 vs 8.9mos. with Optune Lua + docetaxel (n=75) vs docetaxel (n=75)
- Optune Lua is a portable, non-invasive device delivering Tumor Treating Fields via wearable arrays, disrupting electrically charged components of dividing cancer cells to induce their death
Ref: Novocure | Image: Novocure | Press Release
Related News:- Novocure Reports CE Mark Approval of Optune Lua for Metastatic NSCLC (mNSCLC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
